Works matching IS 08876924 AND DT 2012 AND VI 26 AND IP 2

Results: 30

Absence of IL-12R[beta]2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2R[gamma]C-deficient mice.
Published in:
2012
By:
- Ferretti E;
- Montagna D;
- Di Carlo E;
- Cocco C;
- Ribatti D;
- Ognio E;
- Sorrentino C;
- Lisini D;
- Bertaina A;
- Locatelli F;
- Pistoia V;
- Airoldi I
Publication type:
Journal Article
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
Published in:
2012
By:
- McKenzie RC;
- Jones CL;
- Tosi I;
- Caesar JA;
- Whittaker SJ;
- Mitchell TJ
Publication type:
Journal Article
Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment.
Published in:
2012
By:
- Ishihara M;
- Nishida C;
- Tashiro Y;
- Gritli I;
- Rosenkvist J;
- Koizumi M;
- Okaji Y;
- Yamamoto R;
- Yagita H;
- Okumura K;
- Nishikori M;
- Wanaka K;
- Tsuda Y;
- Okada Y;
- Nakauchi H;
- Heissig B;
- Hattori K
Publication type:
Journal Article
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.
Published in:
2012
By:
- Ramakrishnan V;
- Ansell S;
- Haug J;
- Grote D;
- Kimlinger T;
- Stenson M;
- Timm M;
- Wellik L;
- Halling T;
- Rajkumar SV;
- Kumar S;
- Ramakrishnan, V;
- Ansell, S;
- Haug, J;
- Grote, D;
- Kimlinger, T;
- Stenson, M;
- Timm, M;
- Wellik, L;
- Halling, T
Publication type:
journal article
Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 323, doi. 10.1038/leu.2011.198
By:
- McKenzie, R C T;
- Jones, C L;
- Tosi, I;
- Caesar, J A;
- Whittaker, S J;
- Mitchell, T J
Publication type:
Article
Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML.
Published in:
2012
By:
- van der Jagt, A;
- Muirhead, J;
- Seymour, J F;
- Bradstock, K F;
- Paul, E;
- Wei, A
Publication type:
Letter
High Epstein-Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation.
Published in:
2012
By:
- Hoegh-Petersen, M;
- Sy, S;
- Ugarte-Torres, A;
- Williamson, T S;
- Eliasziw, M;
- Mansoor, A;
- Liu, Y;
- Liu, S;
- Podgorny, P;
- Khan, F;
- Duggan, P R;
- Stewart, D A;
- Russell, J A;
- Storek, J
Publication type:
Letter
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 289, doi. 10.1038/leu.2011.200
By:
- Damm, F;
- Bunke, T;
- Thol, F;
- Markus, B;
- Wagner, K;
- Göhring, G;
- Schlegelberger, B;
- Heil, G;
- Reuter, C W M;
- Püllmann, K;
- Schlenk, R F;
- Döhner, K;
- Heuser, M;
- Krauter, J;
- Döhner, H;
- Ganser, A;
- Morgan, M A
Publication type:
Article
ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 265, doi. 10.1038/leu.2011.227
By:
- Bhojwani, D;
- Pei, D;
- Sandlund, J T;
- Jeha, S;
- Ribeiro, R C;
- Rubnitz, J E;
- Raimondi, S C;
- Shurtleff, S;
- Onciu, M;
- Cheng, C;
- Coustan-Smith, E;
- Bowman, W P;
- Howard, S C;
- Metzger, M L;
- Inaba, H;
- Leung, W;
- Evans, W E;
- Campana, D;
- Relling, M V;
- Pui, C-H
Publication type:
Article
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 236, doi. 10.1038/leu.2011.218
By:
- Goh, K C;
- Novotny-Diermayr, V;
- Hart, S;
- Ong, L C;
- Loh, Y K;
- Cheong, A;
- Tan, Y C;
- Hu, C;
- Jayaraman, R;
- William, A D;
- Sun, E T;
- Dymock, B W;
- Ong, K H;
- Ethirajulu, K;
- Burrows, F;
- Wood, J M
Publication type:
Article
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Published in:
2012
By:
- Göhring, G;
- Lange, K;
- Hofmann, W;
- Nielsen, K V;
- Hellström-Lindberg, E;
- Roy, L;
- Morgan, M;
- Kreipe, H;
- Büsche, G;
- Giagounidis, A;
- Schlegelberger, B
Publication type:
Letter
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 349, doi. 10.1038/leu.2011.204
By:
- Boyd, K D;
- Ross, F M;
- Chiecchio, L;
- Dagrada, G P;
- Konn, Z J;
- Tapper, W J;
- Walker, B A;
- Wardell, C P;
- Gregory, W M;
- Szubert, A J;
- Bell, S E;
- Child, J A;
- Jackson, G H;
- Davies, F E;
- Morgan, G J
Publication type:
Article
Absence of IL-12Rβ2 in CD33+CD38+ pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 225, doi. 10.1038/leu.2011.213
By:
- Ferretti, E;
- Montagna, D;
- Di Carlo, E;
- Cocco, C;
- Ribatti, D;
- Ognio, E;
- Sorrentino, C;
- Lisini, D;
- Bertaina, A;
- Locatelli, F;
- Pistoia, V;
- Airoldi, I
Publication type:
Article
How to manage primary amyloidosis.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 191, doi. 10.1038/leu.2011.219
By:
- Gertz, M A
Publication type:
Article
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.
Published in:
2012
By:
- Mihara, K;
- Bhattacharyya, J;
- Kitanaka, A;
- Yanagihara, K;
- Kubo, T;
- Takei, Y;
- Asaoku, H;
- Takihara, Y;
- Kimura, A
Publication type:
Letter
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 199, doi. 10.1038/leu.2011.214
By:
- van de Donk, N W C J;
- Kamps, S;
- Mutis, T;
- Lokhorst, H M
Publication type:
Article
Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 312, doi. 10.1038/leu.2011.222
By:
- Stevanović, S;
- Griffioen, M;
- Nijmeijer, B A;
- van Schie, M L J;
- Stumpf, A N;
- Rutten, C E;
- Willemze, R;
- Falkenburg, J H F
Publication type:
Article
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 244, doi. 10.1038/leu.2011.207
By:
- Negrotto, S;
- Ng, K P;
- Jankowska, A M;
- Bodo, J;
- Gopalan, B;
- Guinta, K;
- Mulloy, J C;
- Hsi, E;
- Maciejewski, J;
- Saunthararajah, Y
Publication type:
Article
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 280, doi. 10.1038/leu.2011.292
By:
- Purandare, A V;
- McDevitt, T M;
- Wan, H;
- You, D;
- Penhallow, B;
- Han, X;
- Vuppugalla, R;
- Zhang, Y;
- Ruepp, S U;
- Trainor, G L;
- Lombardo, L;
- Pedicord, D;
- Gottardis, M M;
- Ross-Macdonald, P;
- de Silva, H;
- Hosbach, J;
- Emanuel, S L;
- Blat, Y;
- Fitzpatrick, E;
- Taylor, T L
Publication type:
Article
Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.
Published in:
2012
By:
- Shanafelt, T D;
- Kay, N E;
- Rabe, K G;
- Call, T G;
- Zent, C S;
- Schwager, S M;
- Leis, J F;
- Jelinek, D F;
- Slager, S L;
- Hanson, C A
Publication type:
Letter
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 296, doi. 10.1038/leu.2011.180
By:
- Marin, D;
- Gabriel, I H;
- Ahmad, S;
- Foroni, L;
- Lavallade, H de;
- Clark, R;
- O'Brien, S;
- Sergeant, R;
- Hedgley, C;
- Milojkovic, D;
- Khorashad, J S;
- Bua, M;
- Alsuliman, A;
- Khoder, A;
- Stringaris, K;
- Cooper, N;
- Davis, J;
- Goldman, J M;
- Apperley, J F;
- Rezvani, K
Publication type:
Article
The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 255, doi. 10.1038/leu.2011.206
By:
- de Vries, J F;
- Zwaan, C M;
- De Bie, M;
- Voerman, J S A;
- den Boer, M L;
- van Dongen, J J M;
- van der Velden, V H J
Publication type:
Article
Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice.
Published in:
2012
By:
- Diamanti, P;
- Cox, C V;
- Blair, A
Publication type:
Letter
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 340, doi. 10.1038/leu.2011.192
By:
- Ramakrishnan, V;
- Ansell, S;
- Haug, J;
- Grote, D;
- Kimlinger, T;
- Stenson, M;
- Timm, M;
- Wellik, L;
- Halling, T;
- Rajkumar, S V;
- Kumar, S
Publication type:
Article
Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model.
Published in:
2012
By:
- Hollink, I H I M;
- Feng, Q;
- Danen-van Oorschot, A A;
- Arentsen-Peters, S T C J M;
- Verboon, L J;
- Zhang, P;
- de Haas, V;
- Reinhardt, D;
- Creutzig, U;
- Trka, J;
- Pieters, R;
- van den Heuvel-Eibrink, M M;
- Wang, J;
- Zwaan, C M
Publication type:
Letter
C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 303, doi. 10.1038/leu.2011.202
By:
- Satoh, Y;
- Matsumura, I;
- Tanaka, H;
- Harada, H;
- Harada, Y;
- Matsui, K;
- Shibata, M;
- Mizuki, M;
- Kanakura, Y
Publication type:
Article
DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL.
Published in:
2012
By:
- Kraszewska, M D;
- Dawidowska, M;
- Larmonie, N S D;
- Kosmalska, M;
- Sędek, Ł;
- Szczepaniak, M;
- Grzeszczak, W;
- Langerak, A W;
- Szczepański, T;
- Witt, M
Publication type:
Letter
Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b+/F4/80+ myeloid cell recruitment.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 332, doi. 10.1038/leu.2011.203
By:
- Ishihara, M;
- Nishida, C;
- Tashiro, Y;
- Gritli, I;
- Rosenkvist, J;
- Koizumi, M;
- Okaji, Y;
- Yamamoto, R;
- Yagita, H;
- Okumura, K;
- Nishikori, M;
- Wanaka, K;
- Tsuda, Y;
- Okada, Y;
- Nakauchi, H;
- Heissig, B;
- Hattori, K
Publication type:
Article
Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 214, doi. 10.1038/leu.2011.217
By:
- Shami, P J;
- Deininger, M
Publication type:
Article
Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.
Published in:
Leukemia (08876924), 2012, v. 26, n. 2, p. 271, doi. 10.1038/leu.2011.199
By:
- Morrison, D J;
- Hogan, L E;
- Condos, G;
- Bhatla, T;
- Germino, N;
- Moskowitz, N P;
- Lee, L;
- Bhojwani, D;
- Horton, T M;
- Belitskaya-Levy, I;
- Greenberger, L M;
- Horak, I D;
- Grupp, S A;
- Teachey, D T;
- Raetz, E A;
- Carroll, W L
Publication type:
Article

Works matching IS 08876924 AND DT 2012 AND VI 26 AND IP 2

Absence of IL-12R[beta]2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2R[gamma]C-deficient mice.

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.

Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment.

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.

Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML.

High Epstein-Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation.

Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia.

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Absence of IL-12Rβ2 in CD33<sup>+</sup>CD38<sup>+</sup> pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.

How to manage primary amyloidosis.

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.

Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia.

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice.

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model.

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.

DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL.

Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b<sup>+</sup>/F4/80<sup>+</sup> myeloid cell recruitment.

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.